Clonal Hematopoiesis in Patients With Nonhematologic Cancers
In a study of nearly 9,000 people treated for solid tumors, researchers found that radiation treatment and tobacco use were linked to higher rates of blood-based DNA mutations that could lead to a higher risk for blood cancers such as leukemia.
The study, published by Coombs et al in Cell Stem Cell, revealed new risk factors for “clonal hematopoiesis,” a medical phenomenon in which genetic mutations are found in the blood cells of patients who do not have an existing blood cancer. Twenty-five percent of the patients in the study had clonal hematopoiesis. Of the subset of patients they actively followed, those with clonal hematopoiesis had a small but increased (+1%) estimated incidence of developing blood cancer later on.
“The presence of clonal hematopoiesis can lead to an increased risk for subsequent blood cancers,” said UNC Lineberger's Catherine Coombs, MD. “We wouldn’t recommend forgoing treatment that is medically indicated, because the risk of a secondary cancer is relatively low, but it is important to closely watch those patients who are at high risk.”
Dr. Coombs was first author of the study at Memorial Sloan Kettering (MSK) Cancer Center, where she completed a fellowship in oncology before coming to UNC Lineberger. The study analyzed genetic changes from 8,810 MSK patients.
Study Findings
The researchers found clonal hematopoiesis in 25% of patients, with the highest incidence in patients with thyroid cancer and the lowest in patients with germ cell tumors. Mutations were more common in older people, with the odds of clonal hematopoiesis increasing 6% for each decade above age 30. Clonal hematopoiesis was also strongly associated with current or former tobacco use.
“A major risk factor for developing clonal hematopoiesis that can be modified or changed is tobacco use,” Dr. Coombs said. The researchers also found a higher frequency of patients with clonal hematopoiesis who had received radiation therapy. Forty-one percent of patients with clonal hematopoiesis received radiotherapy, compared to 35% of patients who did not have clonal hematopoiesis and had received radiotherapy.
Risk for developing a secondary blood cancer was very small in the patient population overall. Only 19 of the 5,394 patients the researchers actively followed developed a new blood cancer within 18 months. However, for patients who did get a blood cancer, the risk was higher for patients who had clonal hematopoiesis. About 1% of patients with clonal hematopoiesis were estimated to develop a secondary cancer, which was 3 times higher than the estimated 0.3% for patients who developed blood cancer and did not have clonal hematopoiesis.
“This has been borne out by other groups: if you have these clonal hematopoiesis mutations, you have a greater risk for developing hematologic cancer than do patients who don’t have them,” she said.
Dr. Coombs said more research is needed to determine the cause of these increases.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
